Pyrimethamine 3D printlets for pediatric toxoplasmosis: design, pharmacokinetics, and anti-toxoplasma activity

ObjectivesThe focus of the present research is to develop printlet formulations of pyrimethamine (PMT).MethodsPrintlets formulation of PMT were developed by screening design by varying laser scanning speed, Kollidon (R) VA 64, polyvinylpyrrolidone, and disintegrant.ResultsLaser scanning speed, Kollidon (R) VA, and disintegrant had statistically significant effect on hardness, disintegration time, and/or dissolution (p < 0.05). Dissolution was almost 100% in 30 min. X-ray powder diffraction indicated partial amorphous transformation of the crystalline drug. Pharmacokinetic and anti-toxoplasma activity profiles of the printlets and compressed tablets were superimposable with no statistical difference (p > 0.05).ConclusionClinical performance of the printlets would be similar to the compressed tablets.

Automated summary

The objective of this research is to develop printlet formulations of pyrimethamine (PMT). Printlets formulations were successfully developed by screening design, which varied the laser scanning speed, Kollidon (R) VA 64, polyvinylpyrrolidone, and disintegrant. The laser scanning speed, Kollidon (R) VA, and disintegrant had a significant impact on the hardness, disintegration time, and/or dissolution. The clinical performance of the printlets is expected to be similar to the compressed tablets.